Shopping Cart 0
Cart Subtotal
USD 0

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Pipeline Review, H2 20

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Pipeline Review, H2 2017

Summary

According to the recently published report 'C-X-C Chemokine Receptor Type 4-Pipeline Review, H2 2017'; C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 26 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

The report 'C-X-C Chemokine Receptor Type 4-Pipeline Review, H2 2017' outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 1, 8 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Cardiovascular, Immunology, Respiratory, Gastrointestinal, Genetic Disorders, Hematological Disorders, Ophthalmology and Women's Health which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Human Immunodeficiency Virus (HIV) Infections (AIDS), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, Uveal Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Asthma, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Liver Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myocardial Infarction, Neuroblastoma, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Thrombocytopenia, Vasomotor Symptoms of Menopause (Hot Flashes), Waldenstrom Macroglobulinemia, Wet (Neovascular / Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects

The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Overview 9

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 16

Products under Development by Universities/Institutes 21

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Therapeutics Assessment 23

Assessment by Mechanism of Action 23

Assessment by Route of Administration 24

Assessment by Molecule Type 26

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Companies Involved in Therapeutics Development 28

AdAlta Ltd 28

Ambrx Inc 29

BioLineRx Ltd 29

Bristol-Myers Squibb Company 30

Eli Lilly and Company 31

Globavir Biosciences Inc 31

GlycoMimetics Inc 32

Pfizer Inc 33

Pharis Biotec GmbH 33

Polyphor Ltd 34

TaiGen Biotechnology Co Ltd 34

Upsher-Smith Laboratories Inc 35

X4 Pharmaceuticals Inc 35

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Drug Profiles 36

AD-114-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ALB-408-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

AM-3114-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

balixafortide-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

BL-8040-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

burixafor-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

GBV-4086-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

GMI-1359-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

HPH-112-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

HPH-196-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

HPH-211-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

hz-515H7-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

LY-2510924-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

PF-06747143-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

POL-5551-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Protein to Agonize CXCR4 for Inflammation-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

PTX-9908-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Q-122-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Recombinant Protein to Antagonize CXCR4 for Oncology-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Synthetic Peptide to Target CXCR4 and SDF-1 for HIV-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

ulocuplumab-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

USL-311-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

X-4P001-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

X-4P002-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Dormant Products 83

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Discontinued Products 87

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Product Development Milestones 88

Featured News & Press Releases 88

Jul 18, 2017: AD-114 safe in non-human primates and manufacturing progress update 88

Jul 10, 2017: BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration 89

Jun 01, 2017: BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors 90

May 25, 2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 90

May 22, 2017: BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML 91

May 08, 2017: AdAlta to present eye fibrosis data at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 91

May 03, 2017: BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA 92

Mar 21, 2017: AdAlta expands collaboration with The Alfred Hospital 92

Mar 20, 2017: BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment 93

Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017 94

Jan 30, 2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease 95

Jan 26, 2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell 95

Jan 18, 2017: AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease 96

Jan 17, 2017: BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer 96

Jan 09, 2017: AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential 97

Appendix 99

Methodology 99

Coverage 99

Secondary Research 99

Primary Research 99

Expert Panel Validation 99

Contact Us 99

Disclaimer 100


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Top 10 Indications, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 24

Number of Products by Stage and Routes of Administration, H2 2017 24

Number of Products by Molecule Types, H2 2017 26

Number of Products by Stage and Molecule Types, H2 2017 26


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Indications, H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15

Number of Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20

Number of Products under Investigation by Universities/Institutes, H2 2017 21

Products under Investigation by Universities/Institutes, H2 2017 22

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Stage and Route of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 27

Pipeline by AdAlta Ltd, H2 2017 28

Pipeline by Ambrx Inc, H2 2017 29

Pipeline by BioLineRx Ltd, H2 2017 29

Pipeline by Bristol-Myers Squibb Company, H2 2017 30

Pipeline by Eli Lilly and Company, H2 2017 31

Pipeline by Globavir Biosciences Inc, H2 2017 31

Pipeline by GlycoMimetics Inc, H2 2017 32

Pipeline by Pfizer Inc, H2 2017 33

Pipeline by Pharis Biotec GmbH, H2 2017 33

Pipeline by Polyphor Ltd, H2 2017 34

Pipeline by TaiGen Biotechnology Co Ltd, H2 2017 34

Pipeline by Upsher-Smith Laboratories Inc, H2 2017 35

Pipeline by X4 Pharmaceuticals Inc, H2 2017 35

Dormant Products, H2 2017 83

Dormant Products, H2 2017 (Contd..1), H2 2017 84

Dormant Products, H2 2017 (Contd..2), H2 2017 85

Dormant Products, H2 2017 (Contd..3), H2 2017 86

Discontinued Products, H2 2017 87

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Therapeutic Products under Development, Key Players in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Therapeutics, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline Overview, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline Assessment


Companies

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Therapeutic Products under Development, Key Players in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Therapeutics, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline Overview, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline Assessment